Streetbeat News

Analyst Ratings

VRTX

Wells Fargo analyst Mohit Bansal has maintained an Overweight rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and increased the price target from $500 to $540.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 4:14 pm

RGA

Wells Fargo analyst Elyse Greenspan has maintained an Overweight rating on Reinsurance Group of America (RGA) and increased the price target from $186 to $193.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 4:13 pm

VRNS

RBC Capital analyst Matthew Hedberg has maintained an Outperform rating on Varonis Systems (NASDAQ:VRNS) and increased the price target from $52 to $56.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 4:12 pm

EL

RBC Capital analyst Nik Modi maintains a Sector Perform rating on Estee Lauder Cos (NYSE:EL) and raises the price target from $115 to $131.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 4:10 pm

MET

Wells Fargo analyst Elyse Greenspan maintains an Overweight rating on MetLife (NYSE:MET) and lowers the price target from $85 to $83.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 4:10 pm

ENSG

RBC Capital analyst Ben Hendrix has maintained an Outperform rating on Ensign Group (NASDAQ:ENSG) and increased the price target from $112 to $133.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 4:09 pm

AFL

Wells Fargo analyst Elyse Greenspan maintains an Equal-Weight rating on Aflac (NYSE:AFL) and raises the price target from $82 to $83.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 4:08 pm

CEG

Wells Fargo analyst Neil Kalton has maintained an Overweight rating on Constellation Energy (NASDAQ:CEG) and increased the price target from $140 to $150.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 4:07 pm

VRTX

RBC Capital analyst Brian Abrahams has maintained a 'Sector Perform' rating on Vertex Pharmaceuticals (VRTX) and increased the price target from $397 to $420.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 4:03 pm

EFTR

HC Wainwright & Co. analyst Robert Burns has maintained a Buy rating on eFFECTOR Therapeutics (NASDAQ:EFTR) and adjusted the price target to $24 from $5, indicating a strong positive outlook for the company.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 4:02 pm